Company Media

Company Media

 

>Nine Finance

Immuron reduces liver inflammation (Mar 2018)

 

>Small Caps

Immuron positive clinical trial results fight fatty liver disease (Mar 2018)

 

>Business Insider

Shares in Australian pharma Immuron are going nuts (Mar 2018)

 

>Seeking Alpha

Immuron's IMM-124E shows encouraging action in mid-stage NASH study (Mar 2018)

 

>Proactive Investors

Immuron shares surge on demonstrating proof of concept for liver drug candidates (Mar 2018) 

 

>Finfeed

Results in: IMC’s lead drug reduces major factor in liver inflammation (Mar 2018)

 

>Next Biotech

Blockbuster Results from IMC’s NASH Liver Therapy Trials (Mar 2018)

 

>Clinical Leader

"How do you recruit patients unaware of their disease?"

 

>Healthyway

"Are These "Unsanitary" Things Really That Bad For You?" (October 2017)

 

>Becker's GI & Endoscopy

"Immuron's fatty liver disease candidate advancing — 4 insights" (September 2017)

 

>  MedCity News

"In dash to NASH, Immuron targets the gut not the liver" (March 2017)

 

>  The Australian Newspaper

"Biotech tackles hospital infection" (March 2017)

 

>  MergerMarket

"Immuron to start search for partner or buyer of fatty liver therapeutics in Q1 2017"  (October 2016)

 

>  ProactiveInvestors.com.au

"Immuron Watches Several High-Value NASH Related Deals"  (January 2017)

 

>  GOOD4UTAH.COM

"Protect Yourself From Mosquito Bites While Traveling This Summer"  (April 2016)

 

>  Arizona Midday

"Healthy and Safe Travel Products"  (April 2016)

 

>  Good Day DC

"What is hot for the Summer Travel Season?"  (March 2016)

 

>   Metro Weekly

"5 Hot Travel Items"  (March 2016)

 

>  What is Travelan and How Does it Work?

https://seekingalpha.com/news/3337676-immurons-immminus-124e-shows-encouraging-action-mid-stage-nash-study-shares-ahead-81-percent